ThioBridge links antibodies and other proteins to drugs. The technology platform is unique in its ability to maintain the stability of the antibody and a consistent Drug-to-Antibody Ratio
Gilead Research and Development executive vice president and chief scientific officer Norbert Bischofberger said: “Direct-acting antiviral treatments have transformed our ability to treat hepatitis C; however, for some
This multicenter trial is designed to assess the feasibility, safety and exploratory efficacy of OTO-104 given by intratympanic administration in subjects at risk for ototoxicity from cisplatin chemotherapy.
The company specializes in the field of opioid addiction, emergency care and sterile injectables. By joining forces with Martindale Pharma, Ethypharm reinforces its presence in the UK. The
Abeona Therapeutics president & CEO Timothy Miller said: “This designation builds on our commercial portfolio of AAV gene therapies that have received FDA and EMA orphan drug designations, which is an
AbbVie company Pharmacyclics and Janssen Biotech are jointly developing and commercializing Imbruvica, which is oral, once-daily therapy that inhibits Bruton's tyrosine kinase (BTK) protein. The approval in MZL
The European Medicines Agency (“EMA”) determined that the intention to treat AS with PBI-4050 was justified based on the preliminary clinical data generated in AS patients showing an
In addition, the FDA removed its partial clinical hold on a dosing ceiling for Resolaris in clinical trials. John Mendlein, PhD, CEO of aTyr Pharma, said: "This Fast
TAK-935 has successfully completed several Phase 1 clinical studies under Takeda’s leadership and will be moving into Phase 1b/2a clinical studies in rare epileptic encephalopathies where patients continue
Boehringer Ingelheim Therapeutic Area Biosimilars senior vice president and head Ivan Blanarik said: “We believe that if approved, BI 695501 can provide a valuable treatment option for the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.